Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReCIPE-B1: Rescuing Cancer Immunotherapy With Plasma Exchange in Bladder Cancer
NCT07087860Phase 2Recruiting
- Sponsor
- Mayo Clinic
- Start
- Aug 2025
- Primary completion
- Aug 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of enfortumab vedotin, pembrolizumab in urothelial carcinoma (UC), sponsored by Mayo Clinic. Started Aug 2025; status: recruiting.
02
Drugs
enfortumab vedotinpembrolizumab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT07087860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07087860.